ライフサイエンスコーパス: neurofibromatosis type 1

1 of cases, primarily in the optic nerve, with neurofibromatosis type 1.

2 r in association with the inherited syndrome neurofibromatosis type 1.

3 as a novel mechanism in the pathogenesis of neurofibromatosis type 1.

4 ith a heterozygous mutation of Nf1 linked to neurofibromatosis type 1.

5 e delay observed in patients with IBMPFD and neurofibromatosis type 1.

6 e plexiform neurofibroma microenvironment of neurofibromatosis type 1.

7 had prior chemotherapy, and 13 patients had neurofibromatosis type 1.

8 n myeloid malignancies from 10 children with neurofibromatosis type 1.

9 contribute to the neoplastic development of neurofibromatosis type 1.

10 d their prognosis related to the presence of neurofibromatosis type 1.

11 major source of morbidity for patients with neurofibromatosis type 1.

12 astatin may prove useful in the treatment of Neurofibromatosis Type 1.

13 ed with tuberous sclerosis complex type 2 or neurofibromatosis type 1.

14 on with the common familial cancer syndrome, neurofibromatosis type 1.

15 a-paraganglioma syndrome and, less commonly, neurofibromatosis type 1.

16 nerve sheath tumors that arise frequently in neurofibromatosis type 1.

17 model to study astrogliosis associated with neurofibromatosis type 1.

18 rowth; inactivating mutations in NF1 lead to neurofibromatosis type 1.

19 their affected parents, in cases of familial neurofibromatosis type 1.

20 ated in leukemic cells in some patients with neurofibromatosis type 1.

21 affected parent of each child with familial neurofibromatosis type 1.

22 strated in leukemic cells from patients with neurofibromatosis type 1.

23 n substantially reduced QOL in patients with neurofibromatosis type 1.

24 the inherited tumor predisposition disorder, neurofibromatosis type 1.

25 of the skin that affect >95% of adults with neurofibromatosis type 1.

26 st common tumor in people with the rasopathy neurofibromatosis type 1.

27 t cause significant mortality in adults with neurofibromatosis type 1.

28 and develop in about 8-13% of patients with Neurofibromatosis Type 1.

29 cur sporadically, after radiotherapy, and in neurofibromatosis type 1.

30 onship to choroidal nodules in patients with neurofibromatosis type 1.

31 s) develop sporadically or in the context of neurofibromatosis type 1.

32 ble plexiform neurofibromas in patients with neurofibromatosis type 1.

33 the more common ophthalmic manifestations of neurofibromatosis type 1.

34 erlie the prevalent familial cancer syndrome neurofibromatosis type 1 [1].

35 (male individuals only 30%; mixed sex 22%), neurofibromatosis type 1 (18%), Down's syndrome (16%), N

36 omplete data) led to a clinical overlap with neurofibromatosis type 1 (35 [28%] of 126).

37 n in the NF1 tumor suppressor gene underlies Neurofibromatosis type 1, a complex disease that enhance

38 s of function variants in the NF1 gene cause neurofibromatosis type 1, a genetic disorder characteriz

39 ing on 479 tissue biopsies from a child with neurofibromatosis type 1, a multisystem cancer-predispos

40 tions in the NF1 tumor suppressor gene cause neurofibromatosis type 1, a pandemic autosomal dominant

41 Although many manifestations of neurofibromatosis type 1 affect the nervous system, othe

42 ing, natural history and how the presence of neurofibromatosis type 1 affects it, unusual presentatio

43 roscopic imaging (MRSI) 9 male subjects with neurofibromatosis type 1 (age, 6-19 years) and 9 age-mat

44 cted pattern of assembly was restored to the neurofibromatosis type 1-Alu template.

45 e sheath tumors often arise in patients with neurofibromatosis type 1 and are among the most treatmen

46 d, such as Angelman syndrome, Rett syndrome, Neurofibromatosis Type 1 and Fragile X syndrome, the cla

47 In this phase 2 trial, most children with neurofibromatosis type 1 and inoperable plexiform neurof

48 arly-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurof

49 PK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurof

50 dromic children, whereas 2 subtypes, JMML in neurofibromatosis type 1 and JMML in children with CBL s

51 ant signaling pathway that is deregulated in neurofibromatosis type 1 and malignant peripheral nerve

52 ed bone marrow samples from 18 children with neurofibromatosis type 1 and myeloid disorders for NF1 m

53 Children with neurofibromatosis type 1 and symptomatic inoperable plex

54 s in plexiform neurofibromas associated with neurofibromatosis type 1 and the use of Ras pathway inhi

55 ned the chromosomal abnormalities present in neurofibromatosis type 1 and type 2.

56 manifestations of genetic syndromes such as neurofibromatosis types 1 and 2 or schwannomatosis.

57 ases including tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome were compa

58 that encompass NF1 cause 5%-10% of cases of neurofibromatosis type 1, and individuals with microdele

59 s a source of dysregulated growth factors in neurofibromatosis type 1, and suggest the further study

60 forms of GIST related to Carney's triad and neurofibromatosis type 1 are discussed in relationship t

61 Tuberous sclerosis and neurofibromatosis type 1 are two pigmentary disorders th

62 Studies of human neurofibromatosis type 1-associated tumors suggest that

63 initially thought to have NS was revised to neurofibromatosis type 1 based on an NF1 nonsense mutati

64 enetics, and cancer screening guidelines for neurofibromatosis type 1, Beckwith-Wiedemann syndrome/ h

65 ular advances in tuberous sclerosis complex, neurofibromatosis type 1, Bloom syndrome, epidermolytic

66 A. beta-catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implic

67 essor NF1 contributes to the pathobiology of neurofibromatosis type 1, but a related role has not bee

68 factor midkine in the skin of patients with neurofibromatosis type 1, but not normal individuals.

69 nd to provide optimum care for patients with neurofibromatosis type 1, clinicians must be aware of th

70 the relative contribution of vision loss and neurofibromatosis type 1 co-diagnosis within a large sam

71 r muscles, lymphedema-distichiasis syndrome, neurofibromatosis type 1, congenital myasthenic syndrome

72 This study shows that, in a mouse model of neurofibromatosis type 1, cortical inhibition is increas

73 Neurofibromatosis type 1-derived Schwann cells isolated

74 Patients with neurofibromatosis type 1 develop aggressive Schwann cell

75 n (phosphatase with tensin homolog) and Nf1 (neurofibromatosis type 1), enhanced filopodial motility.

76 targeting the affected signaling pathways in neurofibromatosis type 1 for the treatment of cognitive

77 To test if loss of the neurofibromatosis type 1 gene (Nf1) compromises fibrobla

78 Mutations in the neurofibromatosis type 1 gene predispose patients to dev

79 sms of 22 anonymous markers and 2 within the neurofibromatosis type 1 gene were performed; two-point

80 n H of the factor IX gene and exon 16 of the neurofibromatosis type 1 gene.

81 SCs from neurofibromatosis type-1 gene (Nf1) null mutant mice sho

82 ant myeloid disorders in young children with neurofibromatosis type 1 is 200 to 500 times the normal

83 Neurofibromatosis type 1 is a common autosomal dominant

84 Neurofibromatosis type 1 is a common autosomal dominant

85 Neurofibromatosis type 1 is a relatively common inherite

86 Neurofibromatosis type 1 is a tumor-predisposing genetic

87 stages of development.SIGNIFICANCE STATEMENT Neurofibromatosis type 1 is associated with cognitive pr

88 Neurofibromatosis type 1 is due to a reduction of the tu

89 A critical event in the pathogenesis of neurofibromatosis type 1 is the heterozygous germ-line l

90 Neurofibromatosis type 1 is the most commonly inherited

91 ately downstream to a T14A11 sequence in the neurofibromatosis type 1 locus.

92 On occasion, neurofibromas in neurofibromatosis type 1 may be present on the lid, brow

93 e, the association of clinical symptoms with neurofibromatosis type 1 might not be appreciated.

94 In neurofibromatosis type 1, molecular assays are being dev

95 ccinate dehydrogenase B-D mutation (n = 21), neurofibromatosis type 1 (n = 1), RET (n = 1), no germli

96 edictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST.

97 Neurofibromatosis type 1 (NF-1) is an autosomal dominant

98 In neurofibromatosis type 1 (NF-1), malignant transformatio

99 Five patients (15%) had neurofibromatosis type 1 (NF-1); four of the five patien

100 el-Lindau (VHL) disease (MIM No 199300), and neurofibromatosis type 1 (NF1) (MIM No 162200).

101 in children with refractory solid tumors and neurofibromatosis type 1 (NF1) -related plexiform neurof

102 Neurofibromatosis type 1 (NF1) affects hearing through d

103 chwann cell-derived tumors characteristic of neurofibromatosis type 1 (NF1) and in animal models of t

104 Neurofibromatosis type 1 (NF1) and Legius syndrome are r

105 ances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis typ

106 Neurofibromatosis type 1 (NF1) and Noonan syndrome (NS)

107 ide approved therapies exist for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperab

108 Multiple tumors are a hallmark of neurofibromatosis type 1 (NF1) and type 2 (NF2) and schw

109 ifferent VA testing methods in children with neurofibromatosis type 1 (NF1) and/or optic pathway glio

110 Children with neurofibromatosis type 1 (NF1) are at increased risk of

111 Children with neurofibromatosis type 1 (NF1) are increasingly recogniz

112 Individuals with neurofibromatosis type 1 (NF1) are predisposed to certai

113 Children with neurofibromatosis type 1 (NF1) are predisposed to juveni

114 Children with neurofibromatosis type 1 (NF1) are predisposed to juveni

115 Children with neurofibromatosis type 1 (NF1) are predisposed to malign

116 Children with neurofibromatosis type 1 (NF1) are prone to learning and

117 Individuals with neurofibromatosis type 1 (NF1) are prone to the evolutio

118 th a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 ger

119 etermine the risk of cancer in patients with neurofibromatosis type 1 (NF1) by cancer type, age, and

120 Children with neurofibromatosis type 1 (NF1) cancer predisposition syn

121 Patients with neurofibromatosis type 1 (NF1) carry approximately a 10%

122 Children with neurofibromatosis type 1 (NF1) carry germline mutations

123 Loss of the tumor suppressor gene NF1 in neurofibromatosis type 1 (NF1) contributes to the develo

124 Patients with neurofibromatosis type 1 (NF1) develop benign plexiform

125 Children with neurofibromatosis type 1 (NF1) develop low-grade brain t

126 The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppresso

127 The gene for neurofibromatosis type 1 (NF1) encodes neurofibromin, a

128 Individuals with Neurofibromatosis type 1 (NF1) experience a high degree

129 ed by the regionally limited distribution of neurofibromatosis type 1 (NF1) features, has been attrib

130 Individuals with neurofibromatosis type 1 (NF1) frequently exhibit cognit

131 The neurofibromatosis type 1 (Nf1) gene encodes a GTPase act

132 The neurofibromatosis type 1 (NF1) gene encodes the GTPase-a

133 le other patients with JCML show loss of the neurofibromatosis type 1 (NF1) gene, a Ras GTPase activa

134 past decade, since the identification of the neurofibromatosis type 1 (NF1) gene, has witnessed great

135 s a number of different genes, including the neurofibromatosis type 1 (NF1) gene.

136 lin heavy chain (IgH) D segment gene and the neurofibromatosis type 1 (NF1) gene.

137 In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mo

138 e imaging for an optic pathway glioma and/or neurofibromatosis type 1 (NF1) had multiple 6 x 6 mm vol

139 A patient with neurofibromatosis type 1 (NF1) had previously been found

140 Individuals with neurofibromatosis type 1 (NF1) have a high incidence of

141 Persons with neurofibromatosis type 1 (NF1) have a predisposition for

142 Genetic disorders such as neurofibromatosis type 1 (Nf1) increase vulnerability to

143 found that loss of the tumor suppressor gene neurofibromatosis type 1 (Nf1) increased HSF1 levels and

144 from tumor cells, we demonstrate how loss of neurofibromatosis type 1 (NF1) increases RAS-GTP levels

145 mors (pilocytic astrocytomas) arising in the neurofibromatosis type 1 (NF1) inherited cancer predispo

146 Individuals with the neurofibromatosis type 1 (NF1) inherited cancer syndrome

147 Neurofibromatosis type 1 (NF1) is a common autosomal dom

148 Neurofibromatosis type 1 (NF1) is a common autosomal dom

149 Neurofibromatosis type 1 (NF1) is a common autosomal-dom

150 Neurofibromatosis type 1 (NF1) is a common cancer predis

151 Neurofibromatosis type 1 (NF1) is a common cancer predis

152 Neurofibromatosis type 1 (NF1) is a common genetic disor

153 Neurofibromatosis type 1 (NF1) is a common genetic disor

154 Neurofibromatosis type 1 (NF1) is a common genetic disor

155 Neurofibromatosis type 1 (NF1) is a common genetic disor

156 Neurofibromatosis type 1 (NF1) is a common genetic disor

157 Neurofibromatosis type 1 (NF1) is a common inherited can

158 Neurofibromatosis type 1 (NF1) is a common monogenic neu

159 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

160 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

161 Neurofibromatosis type 1 (NF1) is a common neurogenetic

162 Neurofibromatosis type 1 (NF1) is a common neurogenetic

163 Neurofibromatosis Type 1 (NF1) is a common neurological

164 Neurofibromatosis type 1 (NF1) is a common tumor predisp

165 Neurofibromatosis type 1 (NF1) is a common tumor-predisp

166 Neurofibromatosis type 1 (NF1) is a commonly inherited a

167 Neurofibromatosis type 1 (NF1) is a dominant genetic dis

168 Neurofibromatosis type 1 (NF1) is a dominant genetic dis

169 Neurofibromatosis Type 1 (NF1) is a genetic condition af

170 Neurofibromatosis type 1 (NF1) is a genetic disease caus

171 Neurofibromatosis type 1 (NF1) is a genetic disease that

172 Neurofibromatosis type 1 (NF1) is a genetic disorder res

173 Neurofibromatosis type 1 (NF1) is a prevalent familial c

174 Neurofibromatosis type 1 (NF1) is a prevalent genetic di

175 Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unk

176 Neurofibromatosis type 1 (NF1) is a rare, autosomal domi

177 Neurofibromatosis type 1 (NF1) is among the most common

178 Neurofibromatosis type 1 (NF1) is an autosomal dominant

179 Neurofibromatosis type 1 (NF1) is an autosomal dominant

180 Neurofibromatosis type 1 (NF1) is an autosomal dominant

181 Neurofibromatosis type 1 (NF1) is an inherited disease i

182 The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical cr

183 The human disease neurofibromatosis type 1 (NF1) is caused by mutations in

184 Neurofibromatosis type 1 (NF1) is characterized by cafe-

185 Neurofibromatosis type 1 (NF1) is one of the most common

186 Neurofibromatosis Type 1 (NF1) is one of the most common

187 Neurofibromatosis type 1 (NF1) is one of the most preval

188 Neurofibromatosis type 1 (NF1) is the most common form o

189 Neurofibromatosis type 1 (NF1) is the most common geneti

190 Neurofibromatosis type 1 (NF1) is the most common monoge

191 exciting discoveries concerning the basis of neurofibromatosis type 1 (NF1) mental retardation, which

192 Astrocytoma (glioma) formation in neurofibromatosis type 1 (NF1) occurs preferentially alo

193 ve sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically.

194 Neurofibromatosis type 1 (NF1) or von Recklinghausen neu

195 deletions, we have identified a new-mutation neurofibromatosis type 1 (NF1) patient who is somaticall

196 Neurofibromatosis type 1 (NF1) patients are predisposed

197 Neurofibromatosis type 1 (NF1) patients are predisposed

198 Neurofibromatosis type 1 (NF1) patients develop benign n

199 Brains from human neurofibromatosis type 1 (NF1) patients show increased e

200 ival rates and the leading cause of death in neurofibromatosis type 1 (NF1) patients under 40 years o

201 e observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to N

202 ression patterns of optic-pathway gliomas in neurofibromatosis type 1 (NF1) patients.

203 Neurofibromas are common tumors found in neurofibromatosis type 1 (NF1) patients.

204 peripheral nerve sheath tumors (MPNST) from neurofibromatosis type 1 (NF1) patients.

205 f dysregulated miRs have not been studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (

206 Neurofibromatosis type 1 (NF1) predisposes individuals t

207 Neurofibromatosis type 1 (NF1) results from mutations in

208 Neurofibromatosis type 1 (NF1) results from mutations in

209 Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation

210 Neurofibromatosis type 1 (NF1) syndrome is caused by ger

211 roma to a malignant sarcoma in patients with neurofibromatosis type 1 (NF1) syndrome remains unclear.

212 (PN) tumors are a hallmark manifestation of neurofibromatosis type 1 (NF1) that arise in the Schwann

213 Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are

214 characterized by biallelic mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene.

215 The neurofibromatosis type 1 (NF1) tumor suppressor protein

216 The human neurofibromatosis type 1 (NF1) tumor suppressor protein

217 neoplasms (SNs) in children with pathogenic neurofibromatosis type 1 (NF1) variants exposed to radia

218 [IQR] follow-up 20 [9.7-20] years), 1783 had neurofibromatosis type 1 (NF1), 444 tuberous sclerosis,

219 Neurofibromatosis type 1 (NF1), a common autosomal domin

220 TOPIC: Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

221 Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

222 tions in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common genetic disorde

223 Neurofibromatosis type 1 (NF1), a common genetic disorde

224 ris) is one of seven diagnostic criteria for neurofibromatosis type 1 (NF1), a common monogenic disor

225 Neurofibromin gene (NF1) mutation causes neurofibromatosis type 1 (NF1), a disorder in which brai

226 y the NF1 gene, the mutation of which causes Neurofibromatosis type 1 (NF1), a genetic disorder chara

227 metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited ge

228 sion profiles in iN cells from patients with neurofibromatosis type 1 (NF1), a single-gene multifacet

229 OPG), seen in 15% to 20% of individuals with neurofibromatosis type 1 (NF1), account for significant

230 Neurofibromatosis type 1 (NF1), an NCFC syndrome, is cau

231 an important ocular finding in patients with neurofibromatosis type 1 (NF1), and early detection of t

232 n, in which loss-of-function mutations cause Neurofibromatosis Type 1 (NF1), contributes to the major

233 In neurofibromatosis type 1 (NF1), deregulation of Ras sign

234 ns in the NF1 tumor-suppressor gene underlie neurofibromatosis type 1 (NF1), in which patients are pr

235 In familial neurofibromatosis type 1 (NF1), individuals with a germ

236 on inherited cancer predisposition syndrome, neurofibromatosis type 1 (NF1), the prevalence of these

237 ging a genetically engineered mouse model of neurofibromatosis type 1 (NF1)-associated optic glioma,

238 This study reports on neurofibromatosis type 1 (NF1)-associated optic pathway

239 Stratum 3 comprised patients with any neurofibromatosis type 1 (NF1)-associated paediatric low

240 omas, OPGs), especially in children with the neurofibromatosis type 1 (NF1)-inherited tumor predispos

241 tions in the NF1 tumor suppressor gene cause Neurofibromatosis type 1 (NF1).

242 ur sporadically in a subset of patients with neurofibromatosis type 1 (NF1).

243 y-resistant tumours arising in patients with neurofibromatosis type 1 (NF1).

244 ng RAS activity via promoting degradation of neurofibromatosis type 1 (NF1).

245 rments are one of the many manifestations of neurofibromatosis type 1 (NF1).

246 and is mutated in humans with the condition neurofibromatosis type 1 (NF1).

247 As arising sporadically and in patients with neurofibromatosis type 1 (NF1).

248 ect tumor susceptibility in a mouse model of neurofibromatosis type 1 (NF1).

249 ith pseudarthrosis (PA), are associated with neurofibromatosis type 1 (NF1).

250 are neoplasms that occur in individuals with neurofibromatosis type 1 (NF1).

251 Mutations in NF1 cause neurofibromatosis type 1 (NF1).

252 ation defects are pervasive in patients with neurofibromatosis type 1 (NF1).

253 derived from 13 patients, seven of which had neurofibromatosis type 1 (NF1).

254 have been implicated in the pathogenesis of neurofibromatosis type 1 (NF1).

255 comas that frequently arise in patients with neurofibromatosis type 1 (NF1).

256 ial model of Schwann cell tumor formation in neurofibromatosis type 1 (NF1).

257 utaneous neurofibromas (cNFs) in people with neurofibromatosis type 1 (NF1).

258 n, and emotional difficulties in people with neurofibromatosis type 1 (NF1).

259 te new treatments for tumors associated with neurofibromatosis type 1 (NF1).

260 r and son with MAS had clinical diagnoses of neurofibromatosis type 1 (NF1).

261 that occur sporadically or in patients with neurofibromatosis type 1 (NF1).

262 primary cause of mortality in patients with neurofibromatosis type 1 (NF1).

263 arcomas that are a leading cause of death in neurofibromatosis type 1 (NF1).

264 oplasms that commonly occur in patients with neurofibromatosis type 1 (NF1).

265 ed autistic trait burden in individuals with neurofibromatosis type 1 (NF1).

266 auses substantial morbidity in patients with neurofibromatosis type 1 (NF1).

267 kin hyperpigmentation are early hallmarks of neurofibromatosis type 1 (NF1).

268 l feature of the common neurogenetic disease neurofibromatosis type 1 (NF1).

269 benign neurofibromas (BNFs) in patients with neurofibromatosis type 1 (NF1).

270 causing the genetic neurocutaneous disorder neurofibromatosis type 1 (NF1).

271 Individuals with neurofibromatosis type-1 (NF1) can manifest focal skelet

272 oradically or in patients with the inherited neurofibromatosis type-1 (NF1) syndrome.

273 ted tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial sc

274 odysplastic syndrome that is associated with neurofibromatosis, type 1 (NF1).

275 Neurofibromatosis type 1 or von Recklinghausen's disease

276 er study of the angiogenic factor midkine in neurofibromatosis type 1 pathogenesis.

277 Neurofibromatosis type 1 patients develop peripheral ner

278 Neurofibromatosis type 1 patients with a submicroscopic

279 Neurofibromatosis type 1 patients with progressive low-g

280 velopment of Schwann cell-derived tumours in neurofibromatosis type 1 patients.

281 mors (MPNST) develop in approximately 10% of neurofibromatosis type-1 patients and are a major contri

282 We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1-related and 2 sporadic cases) t

283 is a highly aggressive sarcoma, and a lethal neurofibromatosis type 1-related malignancy, with little

284 so tested selumetinib using a mouse model of neurofibromatosis type 1-related neurofibroma.

285 l therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas

286 Neurofibromatosis type 1 results from autosomal dominant

287 Segmental neurofibromatosis type 1 (SNF1), characterized by the re

288 years after CRT correlated with patient age, neurofibromatosis type 1 status, tumor location and volu

289 As it is known that children with neurofibromatosis type 1 syndrome have a markedly increa

290 of Nf1, the Ras GTPase gene underlying human neurofibromatosis type 1 syndrome, causes lens dysgenesi

291 at occur sporadically or in association with neurofibromatosis type 1 syndrome.

292 ments in the molecular and biologic bases of neurofibromatosis type 1, tuberous sclerosis, and ectode

293 The neurofibromatosis type 1 tumor suppressor protein neurof

294 th MEN 2B, 1 each with von Hippel-Lindau and neurofibromatosis type 1) underwent adrenalectomy betwee

295 of neurofibromin 1 (Nf1), a gene mutated in neurofibromatosis type 1, unlocked a latent oligodendroc

296 Down syndrome and neurofibromatosis type 1 were the most common CPSs diagn

297 asionally been described in association with neurofibromatosis type 1, whereas an association with ne

298 A patient with neurofibromatosis type 1, which also maps to 17q11.2, an

299 enotype is reminiscent of the human disorder neurofibromatosis type 1, which is characterized by disf

300 ildren with an OPG (sporadic or secondary to neurofibromatosis type 1) who were cooperative for visua